Literature DB >> 7199383

Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture.

W K Yung, J R Shapiro, W R Shapiro.   

Abstract

Six karyotypically distinct clonal cell lines isolated from each of two freshly resected human malignant gliomas were examined for heterogeneity of morphology, in vitro growth rate, and chemosensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea and cis-diamminedichloroplatinum (II). Each clone was identified karyotypically as having come from the parent tumor. The karyotypic deviations were primarily numerical; chromosome numbers ranged from hypodiploid to near-tetraploid. Three morphological types were recognized: astrocyte-like; squamous-like; and fibroblast-like. The growth rates differed among the clones; the doubling times ranged from 48 to 84 hr in those from one tumor and from 72 to 252 hr in the other. Chemosensitivity was measured by cytotoxicity and/or colony-forming assay. In both assays and in both tumors, heterogeneity of chemosensitivity response to both drugs was demonstrated among the different clones from the same tumor. Dose-response curves from some clones differed statistically (log-probit analysis) from those of others, and when the curves were parallel, their 50% effective doses often differed. For the cytotoxicity assay, the 50% effective doses of BCNU ranged from 43 to 94 microgram/ml and for cis-diamminedichloroplatinum (II), from 29 to 340 microgram/ml. For the colony-forming assay, the 50% effective doses of 1,3-bis(2-chloroethyl)-1-nitrosourea ranged from 4.5 to 7.0 microgram/ml and for cis-diamminedichloroplatinum (II), from 0.35 to 1.40 microgram/ml. No correlation was evident between the chromosome number, morphology, growth rates, or chemosensitivities of the clones. These results identified heterogeneity of chemosensitivity among cellular subpopulations in human malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7199383

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Heterogeneity of chemosensitivity in six clonal cell lines derived from a spontaneous murine astrocytoma and its relationship to genotypic and phenotypic characteristics.

Authors:  R Bradford; H Koppel; G J Pilkington; D G Thomas; J L Darling
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

2.  Establishment and characterization of five cell lines derived from human malignant gliomas.

Authors:  J T Rutka; J R Giblin; D Y Dougherty; H C Liu; J R McCulloch; C W Bell; R S Stern; C B Wilson; M L Rosenblum
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

Review 3.  Do anticancer agents reach the tumor target in the human brain?

Authors:  M G Donelli; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Heterogeneity maintenance in glioblastoma: a social network.

Authors:  Rudy Bonavia; Maria-del-Mar Inda; Webster K Cavenee; Frank B Furnari
Journal:  Cancer Res       Date:  2011-05-31       Impact factor: 12.701

Review 5.  Toward an Ising model of cancer and beyond.

Authors:  Salvatore Torquato
Journal:  Phys Biol       Date:  2011-02-07       Impact factor: 2.583

6.  Role of extracellular matrix proteins in regulation of human glioma cell invasion in vitro.

Authors:  S K Chintala; Z L Gokaslan; Y Go; R Sawaya; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1996-09       Impact factor: 5.150

7.  Short-term culture of pediatric brain tumors.

Authors:  W J Mackillop; J Blundell; P Steele
Journal:  Childs Nerv Syst       Date:  1985       Impact factor: 1.475

8.  Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.

Authors:  Roman Reinartz; Shanshan Wang; Sied Kebir; Daniel J Silver; Anja Wieland; Tong Zheng; Marius Küpper; Laurèl Rauschenbach; Rolf Fimmers; Timothy M Shepherd; Daniel Trageser; Andreas Till; Niklas Schäfer; Martin Glas; Axel M Hillmer; Sven Cichon; Amy A Smith; Torsten Pietsch; Ying Liu; Brent A Reynolds; Anthony Yachnis; David W Pincus; Matthias Simon; Oliver Brüstle; Dennis A Steindler; Björn Scheffler
Journal:  Clin Cancer Res       Date:  2016-08-12       Impact factor: 12.531

9.  Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs.

Authors:  S C Barranco; C M Townsend; M A Quraishi; N L Burger; H C Nevill; K H Howell; W R Boerwinkle
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

10.  A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.

Authors:  L G Feun; W K Yung; M E Leavens; M A Burgess; E A Obbens; A Y Bedikian; N Savaraj; D J Stewart; R S Benjamin; W S Fields
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.